SEC Form 4 · accession 0001437749-18-010651
ZEVRA THERAPEUTICS, INC. · ZVRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew R Plooster
Director
Period of report
May 22, 2018
Accepted (ET)
May 24, 2018 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434647
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1,F3 | $6.10 | May 22, 2018 | A | 15,000 | A | — | May 21, 2028 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, May 22, 2018.
- F2This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy.
- F3One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.